Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of SteadyMed Ltd (NASDAQ: STDY) acted responsibly on behalf of investors’ profitability in the planned sale to United Therapeutics Corporation.

On April 30, 2018, SteadyMed Ltd (NASDAQ: STDY) and United Therapeutics Corporation announced that they had entered into a merger agreement. Under the terms of the merger agreement, SteadyMed shareholders will receive $4.46 per share in cash, with an additional $2.63 per share in cash upon achievement of a certain milestone related to SteadyMed’s Trevyent drug-device combination product.

Based in San Ramon, California, and founded in 2005 SteadyMed Ltd operates as a specialty pharmaceutical company that focuses on the development and commercialization of drug product candidates for the treatment of orphan and other diseases with unmet parenteral delivery needs.

The investigation focuses on whether NASDAQ: STDY investors received the highest price and whether the directors of SteadyMed Ltd acted in the best interest of SteadyMed Ltd company and its shareholders.   

If you purchased SteadyMed Ltd (NASDAQ: STDY) prior to April 30, 2018, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185